A treatment for the acute migraine attack.
A compound analgesic/anti-emetic formulation was significantly effective in reducing the severity of acute attacks of migraine, in a double-blind, randomized, crossover trial of 34 patients referred to a migraine clinic. The preparation contained paracetamol (acetaminophen) 500 mg, codeine phosphate 8 mg, buclizine hydrochloride 6.25 mg and dioctyl sodium sulphosuccinate 10 mg. The dosage was two tablets taken as early as possible in the acute attack. No specific factors could be identified which influenced response to treatment. Patients with a long history of migraine (more than 10 years) responded as well as those with a recent onset of the condition.
D000082:Acetaminophen / Q000627:therapeutic use*; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003061:Codeine / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D011897:Random Allocation; D013386:Succinates / Q000627:therapeutic use*
D004338:Drug Combinations; D013386:Succinates; D000082:Acetaminophen; C008528:migraleve; D003061:Codeine